Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib in Relapsed IDH1 Mutated AML Patients Previously Treated With Venetoclax
NCT07471841Phase 2Recruiting
- Start
- Nov 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olutasidenib in acute myeloid leukemia (AML). Primary endpoint: Composite complete remission rate at 2 years. Started Nov 2026; status: recruiting.
02
Drugs
olutasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07471841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07471841.